GlassScriptPhysician profile
Sandeep Kumar Shori
NPI 1790727329
$194,911.67
in general payments reported to CMS, 2019-2025
39 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $11K · 2021: $14K · 2022: $21K · 2023: $34K · 2024: $45K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Honoraria: $9,500 · Travel and Lodging: $6,042 · Food and Beverage: $5,665 · Consulting Fee: $4,000 · Education: $81.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,831.00 |
| Honoraria | $9,500.00 |
| Travel and Lodging | $6,041.98 |
| Food and Beverage | $5,664.60 |
| Consulting Fee | $4,000.00 |
| Education | $81.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56,773.51 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $49,625.36 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,020.00 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $21,574.94 | 2024-2025 | Jardiance |
| Amgen INC. | $17,836.92 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $13,675.60 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $311.91 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $298.82 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $297.72 | 2020-2025 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $289.81 | 2022-2025 | |
| Vifor Pharma, INC. | $234.21 | 2020-2024 | Veltassa |
| Daiichi Sankyo INC. | $234.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $230.47 | 2024-2025 | |
| Baxter Healthcare | $165.85 | 2019-2020 | |
| Medtronic, INC. | $152.29 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $149.81 | 2021 | |
| Glaxosmithkline, LLC. | $128.63 | 2020-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $92.72 | 2019-2023 | Jynarque |
| Ani Pharmaceuticals, INC. | $89.61 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $86.01 | 2024-2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $81.86 | 2023-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $78.32 | 2023 | Rayaldee |
| Scpharmaceuticals INC. | $66.61 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $58.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $42.99 | 2023-2024 | Onpattro |
| Cormedix INC. | $32.91 | 2024 | Defencath |
| Ardelyx, INC. | $30.51 | 2025 | Ibsrela |
| Abiomed | $27.25 | 2025 | |
| Eisai INC. | $26.38 | 2025 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $23.99 | 2022 | |
| Recor Medical INC | $22.31 | 2024 | Paradise Renal Denervation System |
| Dexcom, INC. | $21.22 | 2025 | Dexcom G6 Transmitter |
| Amicus Therapeutics, INC. | $21.14 | 2022 | |
| Genzyme Corporation | $19.28 | 2024 | |
| Abbott Laboratories | $18.61 | 2021 | |
| Chiesi USA, INC. | $17.91 | 2025 | Elfabrio |
| Renalytix Ai, INC. | $15.19 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Shori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.